Every year, the Penington Institute publishes its Australia’s Annual Overdose Report, and every year the Victorian figures carry a quiet, devastating weight: hundreds of lives lost to drug toxicity, most of them in private homes, most of them involving substances that were legally prescribed. Understanding what that data consistently reveals — and what public health experts and harm-reduction advocates say should follow from it — is essential context for anyone trying to make sense of Victoria’s ongoing drug-related health crisis.
This piece is not about any single incident. It is about the patterns that reappear in the Penington Institute’s reporting year after year, and the evidence-based interventions that researchers, clinicians, and community workers argue could reduce the toll.
What the Penington Institute measures — and why it matters #
The Penington Institute, a Melbourne-based public health organisation, compiles its annual report primarily from Australian Bureau of Statistics (ABS) data on drug-induced deaths, cross-referenced with coronial findings and pharmaceutical prescribing records. The methodology matters: because coronial investigations can take years to finalise, the most recent figures in any given report typically reflect deaths from two or three years prior. That lag means the true current toll is almost always higher than what appears on the page.
Victoria consistently accounts for a significant share of Australia’s overdose deaths — broadly in line with its population share, but with particular concentrations in certain demographics and regions. The Institute’s reporting makes clear that overdose is not a crisis confined to people who use illicit drugs. Prescription medications, particularly opioids such as oxycodone and fentanyl, as well as benzodiazepines like diazepam, feature heavily in Victorian fatality data. Polydrug toxicity — where two or more substances interact to suppress breathing — is a recurring factor in a majority of deaths.
Who is most affected in Victoria #
The data paints a picture that challenges many community assumptions. Middle-aged Victorians — particularly men between the ages of 40 and 59 — are consistently among the most at-risk groups in the Penington Institute’s findings. This is not the demographic most people picture when they think of overdose, but it reflects the reality of long-term prescription opioid dependence, often originating in workplace injuries or chronic pain management.
Regional and rural Victoria also appears in overdose data in ways that demand attention. Access to specialist addiction services, pharmacotherapy programs, and mental health support is markedly thinner outside metropolitan Melbourne. The Penington Institute has noted repeatedly that geographic disadvantage compounds individual vulnerability.
First Nations Victorians are disproportionately represented in drug-related mortality statistics — a pattern the Institute frames explicitly within the context of colonisation, intergenerational trauma, and systemic under-investment in culturally safe health services. Any honest reading of the data must hold that context.
The role of naloxone — and the persistent gap in access #
Naloxone is a medication that rapidly reverses opioid overdose. It is safe, it is inexpensive, and it works. Since 2016, naloxone has been available without a prescription in Australia, and in Victoria it can be obtained at many pharmacies at low or no cost under the Pharmaceutical Benefits Scheme.
And yet the Penington Institute has consistently found that naloxone remains vastly underutilised. Most opioid-related deaths in Victoria occur in private residences, often with another person present — a partner, a family member, a housemate — who had no naloxone to hand and no training in how to use it. Public health researchers describe this as a structural failure: a life-saving tool exists, but the systems for getting it to the people who need it most have not kept pace.
Community-based naloxone distribution programs — run through harm-reduction services, needle and syringe programs, and some community health centres — have been shown to save lives in settings where people who use drugs, and those around them, are trained and equipped. Expanding these programs, and normalising naloxone as a household item in the same way an EpiPen is normalised for those with severe allergies, is a recommendation that appears with regularity in evidence-based public health literature.
Supervised injecting and what Victoria’s facility shows #
Victoria’s North Richmond Community Health supervised injecting room — operating under a trial framework since 2018 and subsequently extended — offers a unique lens on harm reduction in practice. The facility allows people to consume pre-obtained drugs under medical supervision, with staff trained to respond to overdose.
Independent evaluations of the North Richmond service have found that it has reversed hundreds of overdoses without a single death on-site, and has connected a significant proportion of its clients with addiction treatment, pharmacotherapy, and social services. The Penington Institute has cited the facility’s data as evidence that supervised consumption services reduce mortality risk for some of the most marginalised people who use drugs.
Debate about the service’s future — its location, its scope, and whether further services should be established elsewhere in Victoria — is a matter of ongoing policy discussion. What the data does not support is the claim that such facilities increase drug use in surrounding communities; peer-reviewed evaluations have found no evidence of that effect.
Pharmacotherapy: the treatment backbone #
Opioid pharmacotherapy — most commonly methadone or buprenorphine, dispensed under medical supervision — is one of the most robustly evidenced interventions available for opioid dependence. People engaged in pharmacotherapy programs have significantly lower rates of overdose death, blood-borne virus transmission, and criminal justice involvement than those not in treatment.
Victoria has one of the more developed pharmacotherapy networks in Australia, with dosing available through specialist clinics, community health services, and an increasing number of community pharmacies. Even so, the Penington Institute’s data and allied research consistently identify unmet demand: people who want to access pharmacotherapy but face barriers including wait times, geographic remoteness, stigma from healthcare providers, and the logistical difficulty of daily dosing for people in unstable housing.
The introduction of long-acting injectable buprenorphine — a monthly or weekly injection rather than a daily dose — has been identified as a significant development in reducing those access barriers, particularly for people whose housing and daily routines make clinic attendance difficult. Uptake in Victoria is growing, though researchers note that awareness among both patients and prescribers remains uneven.
The language we use — and the harm it can do #
Mindframe guidelines, developed by the mental health and suicide prevention sector and widely adopted by health communicators, apply with equal force to reporting on overdose. Words matter. Describing a death as an “accidental” overdose is technically accurate in most coronial findings, but it can also minimise the structural and systemic factors at play. Describing people who use drugs as “addicts” or framing dependence as a moral failing rather than a health condition has been shown to increase stigma, reduce help-seeking, and worsen health outcomes.
At VCN, our approach to overdose reporting follows the principle that people who die of drug toxicity are people — with families, histories, and circumstances that shaped their lives. They are not cautionary tales. The Penington Institute’s annual report is, at its core, a document about preventable deaths, and preventable means something specific: these were not inevitable.
What advocates and researchers consistently ask for #
Across multiple years of Penington Institute reporting and allied research, a set of evidence-based asks recurs: broader naloxone distribution and training; expanded pharmacotherapy access, including in regional and rural areas; sustained funding for peer-led harm-reduction services; culturally safe programs for First Nations communities; and a shift in how the health system — and the broader public — understands drug dependence: as a health issue, not a criminal one.
None of these are new ideas. The evidence base for each is substantial. What the annual overdose report provides, year after year, is a measure of the distance between what is known and what is being done.
If you or someone you know needs support #
- DirectLine (alcohol and drug support, Victoria): 1800 888 236 — 24 hours, 7 days
- Lifeline: 13 11 14 — 24-hour crisis support
- Beyond Blue: 1300 22 4636
- 13YARN (First Nations crisis support): 13 92 76
- 1800RESPECT: 1800 737 732
- Safe Steps (family violence, Victoria): 1800 015 188
- Crime Stoppers: 1800 333 000
Naloxone is available without a prescription at many Victorian pharmacies. Ask your pharmacist about access and training.
